目的:为临床医生提供慢性鼻-鼻窦炎伴鼻息肉病(CRSwNP)患儿生物治疗的最新证据。
方法:PubMed,MEDLINE,科克伦,和临床试验注册。
方法:通过对当前医学文献和临床试验数据库的结构化查询,确定了与儿童CRSwNP中生物治疗相关的关键搜索术语。
结论:针对儿科CRSwNP的生物制剂缺乏积极的临床试验和研究。有一项正在进行的同情使用临床试验,涉及Dupilumab用于鼻息肉儿童,并且只有1篇已发表的工作专门针对Dupilumab用于阿司匹林加重的呼吸系统疾病中的小儿CRSwNP。
结论:对于患有特应性皮炎的儿童,哮喘,和慢性特发性荨麻疹,生物疗法,如奥马珠单抗,Dupilumab,美泊利单抗已获得食品和药物管理局的批准。生物治疗在小儿CRSwNP中的作用表明,在统一气道的综合管理中具有重要意义。需要进行其他III期试验,以扩大患有共病和复杂鼻窦疾病的儿童的临床适应症。
OBJECTIVE: Provide clinicians with current evidence for biologic therapy in children with chronic rhinosinusitis with nasal polyposis (CRSwNP).
METHODS: PubMed, MEDLINE, Cochrane, and clinical trial registries.
METHODS: Key search terms related to biologic therapy in pediatric CRSwNP were identified via a structured query of current medical literature and clinical trial databases.
CONCLUSIONS: There is a dearth of active clinical trials and research studies for biologics targeting pediatric CRSwNP. There is an ongoing compassionate-use clinical trial involving Dupilumab for children with nasal polyps as well as only 1 published work specifically focused on Dupilumab for pediatric CRSwNP in the setting of aspirin-exacerbated respiratory disease.
CONCLUSIONS: For children with atopic dermatitis, asthma, and chronic idiopathic urticaria, biologic therapies such as Omalizumab, Dupilumab, and Mepolizumab have gained Food and Drug Administration approval. The role of biologic therapy in pediatric CRSwNP demonstrates significant promise in the comprehensive management of the unified airway. Additional Phase III trials are necessary to broaden clinical indications for children with comorbid conditions and complex sinonasal disease.